argenx SE (NAS:ARGX)
$ 356.01 -3.47 (-0.97%) Market Cap: 21.22 Bil Enterprise Value: 18.74 Bil PE Ratio: 0 PB Ratio: 5.39 GF Score: 74/100

argenx SE at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 02:30PM GMT
Release Date Price: $129 (-1.71%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

It's only 10:30. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Just quickly before we get started with argenx, I just need to read a quick disclosure statement.

Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So very pleased to have with me argenx and Tim, who's the CEO, with me here. So Tim, I don't know if you want to make any opening comments. But if not, we'll jump right into Q&A.

Tim Van Hauwermeiren
argenx SE - CEO & Executive Director

Let's go straight into Q&A. Thanks for having us today, Matthew.

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Yes. So I thought we'd start with efgartigimod, and there are a lot of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot